Evaluation and Natural History of Children With Cancer and AIDS
Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 9, 2002
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
This protocol will enable the Pediatric Branch to follow selected children with cancer or HIV infection who are not immediately eligible for protocol enrollment but who are likely, within the next year, to become candidates for protocol entry. It will also enable the Pediatric Branch to follow children who present with either clinical findings that constitute important educational experiences for the NCI trainees or who have unique or unusual medical problems that are likely to benefit from the research expertise of the NCI.
Gender
ALL
Eligibility criteria
- • Children with cancer (or a precancer syndrome) or HIV infection, between the age(s) of 3 months to 30 years, who are evaluated by the Pediatric Branch and are found to be not immediately eligible for an ongoing protocol but are likely to become a candidate for a future protocol.
- • Children with cancer (or a precancer syndrome) or HIV infection, who present with disease manifestations of special interest to Pediatric Branch investigators, because they are likely to shed light on disease.
- • Patients who, when evaluated by the Branch, are determined to likely never become eligible for a Pediatric Branch protocol are not eligible for this protocol.
- • No patients younger than 3 months of age or older than 30 years of age are eligible for this protocol.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials